Drug Combination with Radiation for Early-Stage Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) together with chest radiation to treat small cell lung cancer that hasn't spread widely and cannot be removed with surgery. The goal is to see if this combination helps people live longer and controls their cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of limited-stage small cell lung cancer (cancer confined to one side of the chest) that cannot be operated on
- Age 18–75 years old
- No prior chemotherapy or immunotherapy for this cancer
- Good overall health and ability to care for yourself (ECOG score 0–1)
- Blood counts, kidney, liver, and heart function within acceptable ranges
- Ability to swallow pills and absorb oral medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment plan that combines a short course of radiation with chemotherapy and an immunotherapy drug (adebrelimab). It is for people with limited-stage small cell lung cancer who haven't had treatment yet.
This trial tests whether taking tislelizumab plus nintedanib after initial radiation and chemotherapy can help keep limited-stage small cell lung cancer from coming back. It is for people who have finished induction treatment and are in good overall health.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This study tests a new combination of drugs (Benmelstobart immunotherapy plus chemotherapy, with or without Anlotinib) before surgery for people with limited-stage small cell lung cancer. The goal is to see if these drugs help shrink the tumor and improve outcomes.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests whether adding two newer drugs (benmelstobart and anlotinib) to chemotherapy before radiation works better than radiation alone for stage III non-small cell lung cancer that cannot be surgically removed. The goal is to improve survival and control the cancer.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.